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TITLE OF CASE Do not include “a case report” 
Administration of a long acting antipsychotic injection to a child whilst managing contra-
indicated poly-pharmacy interactions and transition between services. 
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
Second generation antipsychotics (SGAs) are used to treat a variety of psychiatric symptoms and 
illnesses as well as the behavioural aspects of various neurodevelopmental disorders. However, 
there is reluctance in using second generation long acting injectable antipsychotics (SG-LAIAs) in 
child psychiatry services. We present a case of a 12yr old child whose presentation and 
medication regime warranted the use of aripiprazole Long Acting (LA) injection against a 
backdrop of potential CYP P450 enzyme interactions as a consequence of poly pharmacy. The 
case also describes the difficulties encountered working across different health sectors and 
agencies and highlights the ongoing need for skills based Continuous Professional Development 
for CAMHS based nursing staff.  
BACKGROUND Why you think this case is important – why did you write it up? 
Second generation antipsychotics (SGAs) are increasingly used in children and adolescents to 
treat a variety of psychiatric illnesses and the behavioural aspects e.g aggression, impulsivity 
associated with various neurodevelopment disorders.[1,2] Whilst the oral use of SGAs is 
becoming more routine within child & adolescent mental health services (CAMHS), prescribers 
can still be wary and reluctant to prescribe the depot or long-acting injectable form of the same 
antipsychotic.[3]  Unfortunately, long acting (depot) formulations of medicines or any type of 
intramuscular administration is often negatively perceived by patients, their families and even 
healthcare staff.  Intramuscular administration of antipsychotics can be a sign that the patient is 
so unwell that they require ‘fast acting’ if not, more potent medication, often within the guise of 
safety or risk containment. The actual physical act of intramuscular administration is often 
negatively portrayed in the media and if not handled sensitively, can also become a source of 
distress for the patient.  The inherent issues associated with drug toxicity, side effects and the 
logistics of administration can make it difficult to encourage greater uptake of long acting/depot 
formulations, and so they tend to be largely prescribed when oral compliance to treatment is 
compromised, either intentionally or unintentionally. The benefits of depot/long acting 
formulations, such as freedom from daily administration of medication, lesser reliance on co-
ordination of ordering repeat prescriptions are however, rarely mentioned. The additional 
governance and patient safety issues associated with using unlicensed medication, further 
complicates their routine use.  This case report aims to show that second generation long-acting 
injectable antipsychotics (SG-LAIAs) can be safely used in children but this requires exceptional 
communication across different sectors and staff who feel competent in its administration.  
CASE PRESENTATION Presenting features, medical/social/family history 
The patient had epilepsy, secondary to Tuberous Sclerosis (TS), diagnosed at age 6yrs and a mild 
Learning Disability.  The patient was admitted age 10½ yrs to a children’s psychiatric ward with a 
history of behavioural and perceptual disturbance over several months.  The patient was clearly 
responding to visual and auditory hallucinations, but could not provide an accurate history as 
she would also become mute on occasions whilst still appearing perplexed and distracted in the 
throes of a psychotic episode. Sleep disturbance and major distress also suggested psychosis.   
The patient was admitted using Mental Health Act legislation and discharged on a Community 
Treatment Order.   
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INVESTIGATIONS If relevant 
An MRI brain scan was performed but did not show any changes from a previous MRI brain 
scan and did not add any clarification 
DIFFERENTIAL DIAGNOSIS If relevant 
NA 
TREATMENT If relevant  
The patient was initially commenced on oral risperidone, at a dose of 500mcg bd which was 
gradually increased over a period of 5 months until it reached a total daily dose of 4mg.  
[carbamazepine 500mg bd, which is a known inhibitor of the P450 CYP 2D6 enzyme, was also 
being prescribed as an anti-epileptic drug (AED) which was why aripiprazole (a substrate for this 
enzyme) was initially considered, but rejected even though its side effect profile is more 
favourable compared to risperidone].  The patient’s response to risperidone was variable and 
given its propensity to increase prolactin levels and the patients age and impending puberty, 
doses were not maximised and another antipsychotic was tried instead.  Given the adverse 
metabolic side effect profile of some SGAs,[4] aripiprazole was deemed as the best option in this 
situation but its co-use with carbamazepine is strongly discouraged due to the effect on plasma 
levels.[5]  Nevertheless, the highly specialist nature of the ward alongside  an experienced 
clinical team (including a specialist psychiatric pharmacist) meant that a decision to persevere 
with the treatment plan of initiating oral aripiprazole (5mg) alongside carbamazepine (500mg 
bd) and continue with low dose lorazepam (0.5-1mg) (to address catatonia) was taken.  This 
combination had a positive effect and the dose of aripiprazole was gradually increased over 8 
months to a maximum oral dose of 15mg daily. Whilst the psychotic symptoms appeared to 
diminish, there were reports of a greater instance of absence type seizures (a possible effect of 
the reduction in seizure threshold caused by the aripiprazole).  The overall improvement in 
presentation and social engagement meant there was reluctance (predominately by the 
parents) to stop the aripiprazole. Instead, a decision was made in consultation with the patient’s 
neurologist to change the AED to oxcarbazepine given its lower propensity for enzyme 
induction. Compliance with oral medication was inconsistent on the ward and on passes home. 
 Social stories were used to aid understanding of the need for medication.  Specialist CAMHS 
Speech and Language Therapist and consultant psychiatrist worked with the patient to gain 
insight into the patient's delusions.  Poor compliance was related to delusions that the 
medication was poisoning the patient.  It was decided that if the psychosis could be treated with 
sustained (peak) levels of antipsychotic it would bring a resolution of the delusions and improve 
overall oral compliance. Interestingly, the social story regarding compliance with medication to 
control menstruation (which was also causing huge distress) was successful, demonstrating that 
the wider social story approach was effective in improving compliance, albeit not for those 
medicines affected by the delusions, i.e the antipsychotics and AEDs. 
To avoid deterioration in mental state and after careful consideration, it was decided that the 
patient would benefit from a monthly intramuscular injection of the long acting form of 
aripiprazole.  This would provide consistent plasma levels of antipsychotic and would also give 
the health care team more frequent contact with the patient and potentially identify much 
quicker if and when the patient’s health started to deteriorate.  
The merits of the long acting form were recognised and largely accepted but there was 
reluctance and anxiety at using a ‘depot’ in someone so young. The detained status of the 
patient meant that a 2nd opinion was required before the treatment could be initiated.  This was 
forthcoming and also helped to provide the necessary safeguards for the clinical team as well as 
the patient.  The problem of managing the interaction and subsequent enzyme induction was 
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still outstanding. Baseline plasma levels of (oral) aripiprazole and its metabolite, 
dehydroaripiprazole, were determined.  The plasma levels in our patient were found to be much 
lower (42 and 19mcg/ml) than the adult reference range of 150-300mcg/ml.  The dose range for 
aripiprazole LA injection is 200-400mg monthly in adults.  Given the relatively low plasma levels 
(against a background of oral oxcarbazepine administration) in our patient, it was decided that 
an initial dose of 300mg IM would be appropriate.  It was reinforced to staff and parents that 
the patient must continue to take the oxcarbazepine as directed- if it was stopped, the enzyme 
inducing effect upon aripiprazole would cease and aripiprazole plasma levels could rise.  Sudden 
Unexplained Death from Epilepsy (SUDEP) was acknowledged to be a risk but there was little 
that could be done given the lack of compliance with the AED. It was felt that the risk was 
justified and accordingly, there was close collaboration between consultant psychiatrist and the 
consultant paediatric neurologist. Additionally, the patient was nursed on 1:1, including 
throughout the night, during the medication transition period as well as deploying camera 
observation to detect seizure activity. Plasma levels were monitored where possible. Oral 
aripiprazole was given for an additional 14 days to allow the LA injection to reach steady state 
plasma levels. No deterioration in functioning was evident doing the transition period and the 
patient was discharged shortly thereafter.  
OUTCOME AND FOLLOW-UP   
Ward nursing experience of administering intramuscular injections in someone so young was 
limited so assistance was sought from the local adolescent unit.  Similarly, when the patient was 
discharged into local authority care to a residential school, issues around the supply of the 
injection also proved challenging.  For example, who would prescribe it and where would it be 
administered? Several iterations involving an ad hoc supply from the (original) children’s ward 
resulted in a plan whereby the medication was prescribed on a GP10 prescription that was 
dispensed at a local community pharmacy.  School staff would collect it from there and together 
with the patient, attend a local CAMHS outpatient clinic for administration by a suitably trained 
nurse.  Additional complexities including the patient’s level of distress at receiving the injection, 
and availability of suitable nursing staff, resulted in the arrangement being untenable.  Plans 
were put in place for the injection to be given at the local adolescent inpatient unit instead. 
Other logistical issues manifested themselves almost on a monthly basis.  Nevertheless, detailed 
planning to allow the community pharmacy to keep the item as ‘stock’ and appropriate record 
keeping (injection administered on a 28 day cycle and NOT monthly)  and ‘named person 
ownership’ by the outpatient team did allow the successful transition and treatment of an 
otherwise very disturbed young person. 
An additional complexity in this particular case was the patient’s refusal to engage in 
antipsychotic (physical health) monitoring due to the level of distress this caused.  This led to the 
need for a detailed risk vs benefit analysis which decided to proceed with the ongoing 
antipsychotic prescription without the required monitoring.  This required engagement with the 
child’s family to provide parental consent and ongoing efforts from community staff to seek 
these investigations at every opportunity.  Whilst it has not been possible to obtain blood or 
cardiac investigations, it has been possible with graded exposure to obtain physical 
observations.  
This patient’s perspective and understanding of the use of an injectable antipsychotic was 
impacted upon because of their learning disability.  The patient lacked capacity to fully engage in 
the decision making process, however was able to clearly communicate distress on attending for 
administration.  Subsequently a transition from injectable to oral antipsychotic was carried out 
which has been successful in managing psychotic symptoms.  This required close observation of 
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the patient’s mental state and consideration of the other co-morbidities.   
DISCUSSION Include a very brief review of similar published cases  
This case demonstrates the importance of ensuring medication compliance in a complex and 
risky situation, especially when there is contra-indicated poly-pharmacy.  The community team 
faced many challenges in successfully administering a long acting/depot antipsychotic due to the 
limited number of staff who felt competent to do so.  It was interesting to note the response of 
colleagues when the patient’s age was taken into consideration and the aversion of some 
professionals as well as the family when considering this type of treatment for this complex and 
seriously unwell person. The practicalities around administering the injection also required 
careful consideration and multi-agency working to ensure that each injection followed a 
carefully curated care plan with appropriate monitoring around it within the confines of a 
patient with reduced capacity.  
The situation also highlighted training issues associated with the administration of injections for 
mental health nurses specialising in CAMHS.  This is perhaps unsurprising given the general lack 
of such procedures in this population compared to nurses specialising in adult mental health 
services.  Service providers should be cognisant of this fact as it could have an impact on nurse 
competencies and their ability to practice safely.    
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
 Second generation long-acting injectable antipsychotics (SG-LAIAs) can be safely used in 
children.  
 Contra-indicated therapies due to Cytochrome P450 enzyme interactions should not 
automatically rule out a particular therapy.  
 Staff working in CAMHS run a risk of becoming deskilled in the administration of injectable 
medication and so should prioritise training in this area.  
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
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PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be written 
by the patient or next of kin 
NA 
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